Omeros (NASDAQ:OMER) Issues Earnings Results

Omeros (NASDAQ:OMER – Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04, Zacks reports.

Omeros Stock Performance

NASDAQ:OMER traded down $0.81 during trading hours on Monday, hitting $16.68. The company’s stock had a trading volume of 1,506,323 shares, compared to its average volume of 1,596,064. The business’s 50-day moving average is $18.27 and its two-hundred day moving average is $13.74. The company has a market capitalization of $1.21 billion, a PE ratio of 13.03 and a beta of 2.96. Omeros has a 52-week low of $6.70 and a 52-week high of $21.24.

Analyst Ratings Changes

A number of research analysts have recently issued reports on OMER shares. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday, July 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $22.00 price objective on shares of Omeros in a research report on Wednesday, October 14th. Finally, Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and a consensus target price of $30.33.

Get Our Latest Report on Omeros

Insider Activity at Omeros

In other news, Director Arnold C. Hanish sold 10,000 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $94,750. This trade represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO David J. Borges sold 10,000 shares of the stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the completion of the transaction, the chief accounting officer owned 5,000 shares of the company’s stock, valued at $104,750. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,906 shares of company stock valued at $1,904,955 over the last 90 days. Company insiders own 10.50% of the company’s stock.

Omeros Company Profile

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Further Reading

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.